Moss, 29 October 2020

Gentian Diagnostics AS announces its results for the third quarter of 2020. The
highlights include:

•	Sales revenue for the first nine months of MNOK 46.1 representing 36 % growth
(24 % adjusted for currency effects) compared to the same period last year

•	Gentian’s Swedish distribution subsidiary, Gentian Diagnostics AB, has had a
sales growth from third party products of 52 % YTD 2020 compared to the same
period last year

•	Scientific Advisory Board for NT-proBNP (formerly called G-1001) Established

•	Study confirms significantly elevated levels of calprotectin in patients with
severe COVID-19, which is an opportunity for our GCAL® assay


Please find the report and results presentation enclosed. The documents will
also be made available on www.gentian.no.


For further information, please contact:


Hilja Ibert

CEO, Gentian Diagnostics

E-mail: hilja.ibert@gentian.no

Cell Phone: +47 919 05 242



Njaal Kind

CFO, Gentian Diagnostics

E-mail: njaal.kind@gentian.no

Cell Phone. +47 919 06 525